NDLI: The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.

Please wait, while we are loading the content...

Year: 2017 Volume: 19

Year: 2016 Volume: 18

Year: 2015 Volume: 17

Year: 2014 Volume: 16

Year: 2013 Volume: 15

Year: 2013 Volume: 15 Issue: 12

Year: 2013 Volume: 15 Issue: 11

Year: 2013 Volume: 15 Issue: 10

Year: 2013 Volume: 15 Issue: 9

Year: 2013 Volume: 15 Issue: 8

Year: 2013 Volume: 15 Issue: 7

Year: 2013 Volume: 15 Issue: 6

When less is more: the forbidden fruits of gene repression in the adult ß-cell.

Higher protein diet for weight management in young overweight women: a 12-month randomized controlled trial.

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.

Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition.

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the ß cell of patients with type 2 diabetes mellitus.

Year: 2013 Volume: 15 Issue: 5

Year: 2013 Volume: 15 Issue: 4

Year: 2013 Volume: 15 Issue: 3

Year: 2013 Volume: 15 Issue: Supplementary 3

Year: 2013 Volume: 15 Issue: 2

Year: 2013 Volume: 15 Issue: Supplementary 2

Year: 2013 Volume: 15 Issue: 1

Year: 2013 Volume: 15 Issue: Supplementary 1

Year: 2012 Volume: 14

Year: 2011 Volume: 13

Year: 2010 Volume: 12

Year: 2009 Volume: 11

Year: 2008 Volume: 10

Year: 2007 Volume: 9

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Jimenez, J. G. Rosen, J. B. Pirags, V. Massaad, R. Hanson, M. E. Brudi, P. Triscari, J.
Description	Country affiliation: Costa Rica Author Affiliation: Jimenez JG ( Hospital CIMA San Jose, Escazu and Universidad de Ciencias Medicas, Sabana Oeste, San Jose, Costa Rica. jjimenez@hospitalcima.com)
Abstract	AIMS: The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). METHODS: This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18-79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. RESULTS: In subjects with MetS, percent changes in LDL-C and other lipids were greater with ezetimibe/simvastatin versus doubling baseline statin or numerically greater versus switching to rosuvastatin, except high-density lipoprotein cholesterol and apolipoprotein (Apo) AI (mean percent changes in LDL-C were: -22.49% ezetimibe/simvastatin, -9.64% doubled baseline statin and -19.20% rosuvastatin). In subjects without MetS, percent changes in LDL-C, total cholesterol and Apo B were greater with ezetimibe/simvastatin versus doubling baseline statin or numerically greater versus switching to rosuvastatin (mean percent changes in LDL-C were: -25.14% ezetimibe/simvastatin, -4.75% doubled baseline statin and -19.75% rosuvastatin). Safety profiles were generally similar. CONCLUSION: These results showed that switching to ezetimibe/simvastatin 10/20 mg was more effective at reducing LDL-C, total cholesterol and Apo B versus doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg regardless of MetS status. These results were generally similar to those of the full cohort.
File Format	HTM / HTML
ISSN	14628902
Issue Number	6
Volume Number	15
Journal	Diabetes, Obesity and Metabolism
e-ISSN	14631326
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2013-06-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Metabolism Discipline Endocrinology Discipline Pharmacology Discipline Diabetology Azetidines Therapeutic Use Cardiovascular Diseases Drug Therapy Cholesterol, Ldl Drug Effects Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetic Angiopathies Metabolic Syndrome X Simvastatin Adolescent Adult Aged Anticholesteremic Agents Apolipoproteins B Blood Atorvastatin Calcium Blood Glucose Prevention & Control Complications Double-blind Method Drug Administration Schedule Drug Combinations Drug Therapy, Combination Ezetimibe, Simvastatin Drug Combination Fasting Female Fluorobenzenes Heptanoic Acids Humans Male Middle Aged Pyrimidines Pyrroles Rosuvastatin Calcium Sulfonamides Treatment Outcome Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in